# A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06038396/  
OnCo record `nct06038396` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RC118-ADC, Toripalimab and RC148 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06038396 by RemeGen Co., Ltd., with 48 participants planned, started 2023-08-03 and due to reach its primary completion in 2026-02-28. Interventions recorded: RC118, Toripalimab and RC148.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06038396
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06038396: https://clinicaltrials.gov/study/NCT06038396

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [RC118-ADC](https://onco.cc/drugs/rc118-adc/), [RC148](https://onco.cc/drugs/rc148/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06038396.json